Viridian Therapeutics, Inc.\DE (VRDN) FCF Margin (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly FCF Margin of 84877.3% for Q1 2026, up 4392686.0% year-over-year from N/an in Q1 2025, and down 366.94% quarter-over-quarter from 18177.27% in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) FCF Margin (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's FCF Margin history runs 14 years deep, the most recent figure standing at 84877.3% for Q1 2026.
- In Q1 2026, FCF Margin rose 4392686.0% year-over-year to 84877.3%; the TTM figure through Mar 2026 stood at 428.42% (up 9240139.0% YoY), while the FY2025 annual figure was 390.81%, up 7670522.0% from the prior year.
- FCF Margin for Q1 2026 stood at 84877.3%, down from 18177.27% in the prior quarter.
- The five-year high for FCF Margin was 120.08% in Q3 2025, with the low at 128804.17% in Q1 2025.
- The 5-year median for FCF Margin is 62809.72% (2024), against an average of 54443.15%.
- Peak annual rise in FCF Margin reached 8383106 bps in 2025, while the deepest fall reached 6599444 bps in 2025.
- Viridian Therapeutics, Inc.\DE's FCF Margin stood at 32243.81% in 2022, then plunged by 64 bps to 52844.44% in 2023, then sank by 93 bps to 102008.33% in 2024, then soared by 82 bps to 18177.27% in 2025, then slumped by 367 bps to 84877.3% in 2026.
- Business Quant data shows VRDN's FCF Margin at 84877.3% in Q1 2026, 18177.27% in Q4 2025, and 120.08% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | -37,545.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -37,545.77% |
| Mar 31, 2026 | -84,877.30% |
| Dec 31, 2025 | -18,177.27% |
| Sep 30, 2025 | -120.08% |
| Jun 30, 2025 | -100,553.33% |
| Mar 31, 2025 | -128,804.17% |
| Dec 31, 2024 | -102,008.33% |
| Sep 30, 2024 | -79,068.60% |
| Jun 30, 2024 | -64,113.89% |
| Mar 31, 2024 | -62,809.72% |
| Dec 31, 2023 | -52,844.44% |
| Sep 30, 2023 | -54,704.17% |
| Jun 30, 2023 | -63,256.94% |
| Mar 31, 2023 | -63,355.10% |
| Dec 31, 2022 | -32,243.81% |
| Sep 30, 2022 | -1,776.90% |
| Jun 30, 2022 | -6,994.92% |
| Mar 31, 2022 | -9,824.54% |
| Dec 31, 2021 | -7,609.81% |
| Sep 30, 2021 | -5,798.56% |